The Library
The Ultimate On-line Candida Resource
Glossary    Contact Us
Browse by Category
Your Are Here >> Library Home > Candida In The Body > Symptoms of Candida > Elevation of Candida IgG antibodies in patients with medically unexplained symptoms


We'd love to hear from you - the Candida Library is for you. Let us know if you have any suggestions, ideas or feedback. Click here to email us.

Elevation of Candida IgG antibodies in patients with medically unexplained symptoms

Dr. Jeff Explains: "This study points out a few important points to consider: 1) The split between what science knows and what the medical profession is unwilling to acknowledge, in spite of the Gold-Standard testing success (randomized, placebo controlled study) of an antifungal drug correcting fungal symptoms; 2) the presence in both testing groups of markers of exposure to Candida albicans; 3) the incidence of a multitude of symptoms with fungal candida infections. If a drug company could even come close to producing the same kind of results produced here with any other drug, it would make front page headlines in every magazine and newspaper in the country. Because itís Candida albicans, it ends up buried here. The FDRQ-7 Questionnaire is a good reference for the variety symptoms that C. albicans can produce, depending on the tissues most affected." - Dr. Jeffrey McCombs

Elevation of Candida IgG antibodies in patients with medically unexplained symptoms.

Lewith GT, Chopra S, Radcliffe MJ, Abraham N, Prescott P, Howarth PH.

School of Medicine, Community Clinical Sciences Research Division, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, United Kingdom.

Erratum in:

  • J Altern Complement Med. 2008 Mar;14(2):219.


BACKGROUND: The hypothesis that an immunologic reaction to Candida yeasts, present in the gastrointestinal tract, causes a diffuse collection of multisystem symptoms is not generally accepted within conventional medicine. A questionnaire, the Fungus Related Disease Questionnaire (FRDQ-7), was previously developed and used to identify patients for a randomized, placebo-controlled trial of the nonabsorbed antifungal drug nystatin. Nystatin was superior to placebo in relieving these symptoms. This provides some support for the hypotheses that underpin the "Candida syndrome".

AIM: The aim of this study was to identify a population with a high (>9) FRDQ-7 score and symptom-free controls and, subsequently, to explore the relationship between FRDQ-7 scores and Candida immunoglobulin (Ig)A, IgG, and IgM levels.

DESIGN: This was a case-controlled study.

METHODS: Santelmann has suggested that the FRDQ-7 describes people with Candida syndrome if the FRDQ-7 score is >9; 35 patients with medically unexplained symptoms, between ages 18 and 64, were selected for the study if they scored > 9 on the FRDQ-7 questionnaire. Serum Candida IgA, IgG, and IgM measurements were undertaken both for this group and a group of 45 healthy age- and gender-matched controls, and the Ig concentrations were compared.

RESULTS: Candida IgG concentration was significantly higher in the noncontrol group than in the control group (p < 0.001). No significant difference was found for Candida IgA or IgM concentrations.

CONCLUSIONS: Further studies are required to identify whether there is a causal link for the elevation of serum IgG found in this subgroup of patients with increased FRDQ-7 scores, or whether these two observations are parallel manifestations of a common underlying disorder.

PMID: 18166126 [PubMed - indexed for MEDLINE]


Keywords: FRDQ FDRQ-7 Questionnaire symptoms systemic Candida syndrome multi-symptom unexplained IgG antibodies drjefftop

Rate This Article: